Business
Accendra provides home healthcare equipment, medical supplies, related services, and clinical and administrative support to patients under payor arrangements.
Accendra grew revenue and drew a large investor buy, but net loss ballooned and equity turned negative.
The read at a glance✓ Audited against SEC data
- Business mix — Home healthcare equipment and suppliesNote
- Revenue — Revenue +3.1% to $2.762BOK
- Profitability — Net loss widened to $1.101BWatch
- Margins — Gross margin fell to 46.68%Watch
- Balance sheet — Equity turned negative at -$461MWatch
- Insiders — 3 buys / 0 sells; $8.1M boughtOK
- Accounting — Altman-Z distressWatch
Where the revenue comes from
Fiscal 2025, as ACCENDRA HEALTH INC/VA/ reports it. History and quarterly detail are in the app.
- Diabetes Product$783.4M
- Sleep Therapy Product$740.1M
- Home Respiratory Therapy Product$433.1M
- Product And Service Other$288.2M
- Ostomy$212.8M
Leadership changes
From ACCENDRA HEALTH INC/VA/'s own filings, the day they're filed.
- Perry A. Bernocchi · President · appointmenteff. 2025-12-05
- Jonathan A. Leon · President · appointmenteff. 2024-09-23
- Jonathan A. Leon · Chief Financial Officer · appointmenteff. 2024-06-21
Latest filings
- 8-K · Company announcement2026-08-17
- 8-K · Company announcement2026-08-10
- 10-Q · Quarterly report2026-08-10
- 8-K · Company announcement2026-08-10
- 8-K · Company announcement2026-08-10
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about ACCENDRA HEALTH INC/VA/, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.